BMI believes the commercial success of the pharmaceutical industry depends on innovation to a much greater extent than any other industry. The long-term success of the sector is highly dependent on maintaining a steady rate of new product launches, to replace older products with expired patents and recover revenues lost to the generic drug sector…. [Read more]
BMI’s newest core view is that private healthcare spending as a percentage of total healthcare expenditure in emerging markets will decrease over the medium term. Governments in these countries increasingly appreciate the value of a healthy population and are boosting investment in medical services, such as pharmaceuticals, diagnostics, doctors, nurses, clinics and hospitals. Notable public… [Read more]
When Fujifilm announced a ‘full-scale entry’ into the pharmaceutical sector earlier this year, many market observers were left head scratching. Surely companies should focus on their core competencies? What does Fujifilm know about developing and selling medicines? Who is going to buy these drugs? I, on the other hand, saw the beginning of a trend… [Read more]